Novozymes and Sanofi-Aventis Collaborate for Potential Antibiotic
Novozymes (Bagsvaerd, Denmark) has entered into a global licensing and collaboration agreement with Sanofi-Aventis (Paris, France) for the development and marketing of a new potential antibiotic.
Novozymes (Bagsvaerd, Denmark) has entered into a global licensing and collaboration agreement with Sanofi-Aventis (Paris, France) for the development and marketing of a new potential antibiotic.
The drug candidate, developed by Novozymes, is an antimicrobial peptide named Plectasin NZ2114, a variant of plectasin, for the treatment of severe infections, such as pneumonia and septicemia, caused by resistant and sensitive gram-positive bacteria like Staphylococcus and Streptococcus.
Under the terms of the agreement, Sanofi-Aventis has been granted an exclusive worldwide license for the development, registration, and commercialization of the drug. The two parties will jointly work to develop and implement commercial-scale manufacturing of the Plectasin NZ2114 drug substance.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
